Acasti Pharma (ACST) Stock Price, News & Analysis

Company Overview

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Key Stats

• Today's Range: $3.03 to $3.14
• 50-Day Range: $2.56 to $3.60
• 52-Week Range: $1.98 to $3.60
• Volume: 12,261 shs
• Average Volume: 22,722 shs
• Market Capitalization: $29.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

ACST Stock Analysis - Frequently Asked Questions

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) announced its earnings results on Friday, June, 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.30.

When did Acasti Pharma's stock split?

Acasti Pharma's stock reverse split on Monday, July 10th 2023.The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 6/21/2024
• Today: 7/12/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACST
• CIK: 1444192
• Web: www.acastipharma.com
• Phone: 45-0686-4555
• Fax: 45-0687-2272
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acasti Pharma: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +221.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -13.61%
• Return on Assets: -11.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.86
• Quick Ratio: 7.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.57 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 9,399,000
• Free Float: 8,770,000
• Market Cap: $29.23 million
• Optionable: Not Optionable
• Beta: 1.52